ABSTRACT Avian species have a unique renal structure and abundant blood flow into the kidneys. Although many birds die due to nephrotoxicity caused by chemicals, there are no early biomarkers for renal lesions. Uric acid level in blood, which is generally used as a renal biomarker, is altered when the kidney function is damaged by over 70%. Therefore, early biomarkers for kidney injury in birds are needed. In humans, glycomics has been at the forefront of biological and medical sciences, and glycans are used as biomarkers of diseases, such as carcinoma. In this study, a glycomics approach was used to screen for renal biomarkers in chicken. First, a chicken model of kidney damage was generated by injection of diclofenac or cisplatin, which cause acute interstitial nephritis (AIN) and acute tubular necrosis (ATN), respectively. The nephrotoxicity levels were determined by a blood chemical test and histopathological analysis. The plasma N-glycans were then analyzed to discover renal biomarkers in birds. Levels of 14 glycans increased between pre-and post administration in kidney-damaged chickens in the diclofenac group, and some of these glycans had the same presumptive composition as those in human renal carcinoma patients. Glycan levels did not change remarkably in the cisplatin group. It is possible that there are changes in glycan expression due to AIN, but they do not reflect ATN. Although further research is needed in other species of birds, glycans are potentially useful biomarkers for AIN in avian species.
INTRODUCTION
Avian species have a unique kidney structure with abundant blood flow into the kidneys (Harr, 2002) because of the renal portal veins. This system does not exist in mammals (Lierz, 2003) , and the avian kidney is vulnerable to various chemicals from the blood.
Indeed, many birds die due to nephrotoxicity caused by chemicals. In the Indian subcontinent, over 90% of 3 vulture species were killed by the non-steroidal antiinflammatory drug (NSAID), diclofenac (Green et al., 2004; Swan et al., 2006) . Diclofenac was used for the medical treatment of cattle, and the drug was acciden-C 2018 Poultry Science Association Inc. Received September 4, 2017. Accepted January 11, 2018. 1 Corresponding author: ishizum@vetmed.hokudai.ac.jp tally ingested by vultures when they consumed cattle carcasses (Oaks et al., 2004) . It has been reported that primary cultures of avian kidney cells were much more susceptible to diclofenac than mammalian cell cultures (Naidoo and Swan, 2009 ). In addition, other NSAID, such as ketoprofen, cause renal lesions in birds as a side effect (Mohan et al., 2012) . Furthermore, lead (Pb), mercury (Hg), and other therapeutic agents, such as anticancer drugs and antifungal agents, cause renal toxicity in birds (Johnson, 1998; Wolfe et al., 1998; Joseph, 2000; Filippich et al., 2001 ). In the case of humans, drug-induced kidney injury is a serious problem in clinical practice and accounts for 19 to 26% of cases of acute kidney injury (AKI) among hospitalized patients (Hosohata, 2016) . In avian species, there have been many reports of renal damage in both wild birds and companion birds.
The diagnosis of kidney disease in birds is challenging. Generally, uric acid (UA) level in blood is used as a renal biomarker in birds. However, UA is not an early biomarker because its levels can be altered when the kidney function is damaged by >70% (Lierz, 2003) . The end product of protein metabolism in birds is UA, and because most of the UA in the urine is in an insoluble form, it does not have an osmotic effect (Styles and Phalen, 1998) . Furthermore, as most UA is secreted from the proximal tubules and not filtered, blood UA levels will not be affected by moderate changes in the glomerular filtration rate (GFR) (Styles and Phalen, 1998) . Even in the event of extensive tubular disease, polyuria and resultant polydipsia and the resulting increase in glomerular filtration can maintain UA levels within the normal range. Therefore, UA concentrations may not reflect glomerular disease, and widespread tubular disease also may be present long before UA levels rise above normal. Diagnosis of kidney disease is further complicated in that it is difficult to obtain urine samples from birds because the ureter opens into the cloaca, and the urine is stored in the cloaca or intestine until defecation of a semisolid mixture of urine and feces (Skadhauge, 1968) . The level of phosphorus is not changed commonly in all species of birds although the concentration increases due to renal lesions in some avian species (Tully et al., 2009) . Therefore, discovery and identification of novel biomarkers for kidney injury in birds are required.
Genomics and proteomics approaches are generally used for the discovery of biomarkers. Glycomics is also a useful tool to identify biomarkers (Adamczyk et al., 2012) . Glycosylation is a frequent co-/posttranslational modification of proteins, which modulates a variety of biological functions (Dall'Olio et al., 2013) . Glycan structures on newly synthesized glycoproteins are crucial for protein secretion (Moremen et al., 2012) . Over 50% of proteins are glycosylated in humans, and the effects of disease states on glycan biosynthesis can be more evident than those on proteins (Adamczyk et al., 2012) . It has been reported that glycans in humans may potentially be used as biomarkers of renal carcinoma (Hatakeyama et al., 2014) . Therefore, it is possible that glycans would be useful as biomarkers in birds.
The present study was performed to identify novel renal biomarkers in avian species for the conservation and to develop cures for wild birds as well as companion birds. First, a model of kidney damage was generated in chickens by injection of diclofenac or cisplatin, and renal biomarkers were examined. Acute kidney injury includes acute interstitial nephritis (AIN) and acute tubular necrosis (ATN) (Hosohata, 2016) ; diclofenac causes AIN, whereas cisplatin causes ATN. Diclofenac caused severe nephrotoxicity in birds as mentioned above, and the anticancer drug, cisplatin, induces renal lesions as a side effect and is used to make models of kidney injury in rats (Pinches et al., 2012) . The kidney shows greater accumulation of cisplatin than other organs, and the kidney is the major route for its excretion (Yao et al., 2007) . To our knowledge, this is the first study to use glycomics to discover biomarkers in birds. Plasma N-glycans in chicken were analyzed by glycoblotting, which can be used for high-throughput analysis of biological samples (Hirose et al., 2011) , along with matrix-assisted laser desorption ionization, timeof-flight mass spectrometry (MALDI-TOF MS), and they were profiled to discover novel biomarkers for kidney injury in avian species.
MATERIALS AND METHODS

Animal Experiments
All experimental protocols were approved by the Laboratory Animal Care and Use Committee of Graduate School of Veterinary Medicine, Hokkaido University, Japan. The animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals, which conforms to the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) (approval number: 14-0119). The endpoints were weight loss >20% compared to pre-injection, or severe clinical symptoms. Euthanasia was carried out by carbon dioxide inhalation under anesthesia by an overdose of isoflurane (Abbott Laboratories, Chicago, IL) after fasting for over 12 hours. The animals were monitored twice per d during the administration period to check their health. Their body weight was measured from pre-administration to the final d of the experiment. A 27 G needle was used for injection to reduce pain and stress.
Experimental Design
Male white leghorn chickens (Gallus gallus domesticus) (n = 15, 10 wk old, body weight: 1.2 to 1.4 kg) were purchased from Hokudo Co., Ltd. (Tokyo, Japan) and were housed under conditions of constant temperature (20 ± 2
• C) and humidity (40 ± 10%), with a 12:12 h light: dark cycle and given food and water ad libitum. They were allowed to acclimatize to the environment for one wk before commencement of the experiment. Animals were divided into the following 4 groups: (1) control group (injection of 20% DMSO, n = 3: Cont. −1, −2, −3); (2) diclofenac sodium group A (1.5 mg/kg body weight, n = 4: A-1, -2, -3, -4); (3) diclofenac sodium group B (2.0 mg/kg body weight, n = 4: B-1, -2, -3, -4); and (4) cisplatin group (3.5 mg/kg body weight, n = 4: C-1, -2, -3, -4). Injection doses were considered according to reference papers of diclofenac treatments (Naidoo et al., 2007; Jain et al., 2009; Mohan et al., 2012) or cisplatin administrations (Cacini and Fink, 1995; Filippich et al., 2001) .
Pre-administration plasma was collected one wk after arrival. Administration was started after a further one week. The control group received injection of 20% dimethyl sulfoxide (DMSO) (Nacalai Tesque, Kyoto, Japan) diluted in saline once daily in the morning for 4 consecutive days. The treatment groups received administration of diclofenac sodium diluted in 20% DMSO into the pectoral muscle once daily in the morning for 4 consecutive d, or a single dose of cisplatin (Wako Pure Chemical Industries, Osaka, Japan) diluted in saline into the basilic vein. Control and diclofenac groups were euthanized on d 5 after the first administration, whereas the cisplatin group was euthanized on d 3 because of the endpoint of clinical signs.
Blood Collection
Blood collection (6 mL) from the basilic vein was carried out pre-and post injection in the morning (from 9:00 a.m.) using a 23 G or 24 G needle and heparincontaining syringe. Regarding the post injection, administration was started just after the blood collection. Whole blood was stored on ice after collection, and plasma was prepared by centrifugation within 2 h after collection. Centrifugation was performed at 1630 × g for 20 min at 4
• C. Plasma specimens were immediately frozen in liquid nitrogen and stored at -80
• C.
Tissue Sample Collection
Chickens were euthanized with an overdose of isoflurane (Abbott Laboratories) and carbon dioxide. After euthanasia, the kidneys, liver, lungs, and heart were collected. The weights of the whole body, liver, and kidney were measured. The excised tissues were cut into small pieces and stored in 10% neutral buffered formalin for histopathological analysis.
Blood Tests
Aspartate aminotransferase (AST), total plasma protein (TPP), lactate dehydrogenase (LDH), creatine phosphokinase (CK), inorganic phosphate (P), and calcium (Ca) levels were determined using Cobas Ready R (Roche Diagnostics K.K., Basel, Switzerland). The upper detection limit of UA by COBAS is 20 mg/dL, and UA in birds with high degrees of kidney damage exceeds this level. Therefore, UA level was analyzed by high-performance liquid chromatography separation and ultraviolet detection (HPLC-UV, 20A series; Shimadzu, Kyoto, Japan). The significance of each test is shown in the Supporting Information (Text S1 in Supporting Information).
For measurement of hematocrit (Ht), 200 μL of whole blood was collected from the basilic vein before dissection using a 24 G needle without heparin and immediately moved into tubes containing ethylenediaminetetraacetic acid (EDTA). Ht level was measured using a microhematocrit centrifuge (Kubota 3220; Kubota Corporation, Tokyo, Japan) at 15,000 × g for 5 minutes.
Uric Acid Analysis by HPLC
Analyses were performed by HPLC-UV (20A series; Shimadzu), and the improved HPLC method of the Japan Society of Clinical Chemistry (JSCC) was used for measurement of UA. Briefly, 25-μL aliquots of plasma specimens or standard solution were mixed with 225 μL of 0.3 mol/L perchloric acid and cooled on ice for 30 minutes. The samples were mixed again by vortexing and centrifuged at 750 × g for 10 min at 4
• C. Aliquots of 150 μL of the supernatants were collected and centrifuged again at 750 × g for 10 min at 4
• C. Then, 50-μL aliquots of the supernatants were collected and moved to HPLC vials, followed by addition of 50 μL of 10 mM ammonium acetate. For HPLC calibration, 100.3 mg of UA (Wako Pure Chemical Industries) were dissolved in 0.01 mol/L lithium carbonate and made up to 100 mL (1 g/L). Standard solutions (1.25, 2.5, 5, 10, 25, and 50 mg/L) were diluted with deionized distilled water. A UV detector set at 284 nm was used to monitor the effluent. Mobile phase A consisted of 10 mM ammonium acetate (pH 4.8), and phase B consisted of 100% methanol. An Inertsil ODS-3 column (2.1 mm × 150 mm: GL Sciences, Inc., Tokyo, Japan) was used for separation at a flow rate of 0.2 mL/min, and the injection volume was 5 μL. The R 2 value of the linear regression line was 0.998.
Histopathological Analysis
Paraffin-embedded kidney sections were stained with periodic acid-Schiff, and liver, heart, and lung sections were stained with hematoxylin and eosin.
Glycoblotting-based Plasma Glycomics
Analyses of N-glycans were performed according to the methods of Kamiyama et al. (Kamiyama et al., 2013) . Plasma specimens were pretreated for release of N-glycans and subjected to glycoblotting for enrichment and quantification of N-glycans prior to MALDI-TOF/MS. Briefly, pretreatment of plasma glycoproteins was performed to release whole N-glycans using PNGase F. Glycans were selectively captured by glycoblotting using BlotGlyco R beads. Methyl esterification of sialic acid residues and transiminization reaction to tag N-glycans with benzyloxyamine (BOA) were carried out on the beads. BOA-tagged N-glycans were subjected to MALDI-TOF/MS analysis. More details regarding pretreatment, glycoblotting, mass spectrometry, and data analysis are presented in S2 Text. Expression levels of each glycan were expressed by the ratio with the plasma mixture of healthy chickens.
Statistical Analysis
To compare the results of biochemical analyses between pre-and post administration, the weight of Table 1 . Plasma concentrations of UA (uric acid), P (inorganic phosphate), Ca (calcium), AST (aspartate aminotransferase), LDH (lactate dehydrogenase), CK (creatine phosphokinase), and TPP (total protein) in diclofenac-or cisplatin-treated and control chickens.
Pre-injection
24 h 48 h 72 h 96 h UA (mg/dL) 5.0 ± 0.5 3.2 ± 0.3 2.4 ± 1.0 2.7 ± 0.6 2.9 ± 0.6 P (mg/dL) 7.1 ± 0.5 6.2 ± 0.4 6.4 ± 0.6 6.1 ± 0.0 6.1 ± 0.9 Ca (mg/dL) 9.7 ± 0.5 9.6 ± 0.5 9.8 ± 0. 2.9 ± 0.1 2.7 ± 0.3 2.9 ± 0.3 2.9 ± 0.3 2.6 ± 0.5 UA (mg/dL) 4.4 ± 1.0 3.7 ± 1.0 3.8 ± 1.2 72.9 ± 117.8 48.8 ± 78.6 P (mg/dL) 7.5 ± 0.3 6.8 ± 0.7 7.0 ± 0.4 8.1 ± 1.4 8.8 ± 3.2 Diclofenac A Ca (mg/dL) 9.9 ± 0.2 9.7 ± 0.2 9.3 ± 0.1 9.3 ± 0. (2.0 mg/kg, P (mg/dL) 7.9 ± 0.7 7.2 ± 0.8 7.3 ± 0.9 * 3 7.9 ± 1.2 * 3
6.1 ± 1.1 * 3 n = 4) Ca (mg/dL) 9.8 ± 0.3 9.7 ± 0.1 9.2 ± 0.6 9.6 ± 0.4 * 3 9.5 ± 0. 
2.9 ± 0.2 2.9 ± 0.3 2.9 ± 0.3 3.1 ± 0.6 * 3
2.8 ± 0.4 * 3
Ca (mg/dL) 10.5 ± 0.5 10.9 ± 0.3 11.6 ± 1.5 --
3.4 ± 0.2 3.8 ± 0.0 3.3 ± 0.6 -- * The values were calculated from one chicken * 1 , 2 chickens * 2 , or 3 chickens * 3 , because the others exceeded the detection limit (LDH: 3937 IU/L, CK: 2000 IU/L).
In diclofenac group B, one chicken died on the third d of administration. There were no significant differences between pre-and post administration (Steel's test, P < 0.05).
the body and tissues between controls and treatment groups were analyzed by Steel's test. For comparison of renal damage scores and glycan levels among chickens, data were analyzed using Spearman's rank correlation coefficient. Statistical analyses were performed using JMP Pro 13 (SAS Institute, Cary, NC). In all analyses, P < 0.05 was taken to indicate statistical significance.
RESULTS
Clinical Signs
In the diclofenac-treated group, chicken B-1 showed depressed activity and polyuria from the second d of administration and was dead on the third day. Therefore, regarding chicken B-1, blood samples were collected until the third day. Chicken A-1 also showed weakness from the fourth day. All 4 cisplatin-treated chickens had polyuria and depressed activity from the second day. The other chickens generally appeared normal. The control group did not show any symptoms.
Biochemical Analysis
The plasma concentrations of UA, P, Ca, AST, LDH, CK, and TPP as indicators of various tissues are shown in Table 1 . The normal UA concentration in chickens ranges from 2.5 to 8.1 mg/dL (Miller and Fowler, 2014) . Although there were no significant differences between pre-and post administration in any of the groups, several chickens in the treatment groups showed high levels of UA. In the diclofenac group, chicken A-1 exceeded the normal UA level 72 h after injection. Chickens B-1 and B-2 showed high levels of UA after 24 h, and the level in chicken B-4 increased after 72 hours. However, the UA level in chickens B-2 and B-4 recovered after 96 hours. In the cisplatin group, UA level was high in all chickens 48 h after the injection, and markedly exceeded the reference level. As other indicators of renal lesions, P concentration was also elevated in some of these chickens; the reference level in chicken is 6.2 to 7.9 mg/dL (Miller and Fowler, 2014) . Although AST level of chickens in the treatment group increased, the levels were within the normal range for turkeys of 255 to 499 IU/L, and the LDH level exceeded the reference level for turkeys of 420 to 1338 IU/L (Miller and Fowler, 2014) .
Gross Pathology
All cisplatin-treated chickens, and chickens A-1, B-1, and B-2 in the diclofenac group showed pale kidneys compared with the controls (Fig. 1) . Kidneys in these chickens were enlarged, although there were no significant differences in kidney weight between controls and each exposure group (Table S1 ). The control group and the other chickens in the treatment groups did not show any gross pathological changes. The liver specimens in all chickens had no lesions, and there were no significant differences in tissue weight (Table S1 ).
Histopathological Analysis
All cisplatin-treated chickens and 4 diclofenactreated chickens showed renal damage (Fig. 2) . Although they commonly showed degenerative and necrotic lesions in the proximal and distal tubules, and sometimes glomeruli, and the shape of nuclei in the proximal tubules became unclear, the histology was different between diclofenac and cisplatin groups. Diclofenac-treated chickens showed the infiltration of leukocytes such as heterophils in interstitium. In the cisplatin group, necrosis of tubules was shown, and many proteinaceous casts in the tubular lumen also were found. In addition, tubular epithelial cells were detached from the basement membrane of some tubules in chickens A-1 and B-1 in the diclofenac group and all cisplatin-treated chickens. Chickens B-2 and B-4 in the diclofenac group showed mild degenerative lesions, such as slight dilation of proximal and distal tubular lumens. Chickens A-2, A-3, A-4, and B-3 appeared normal.
According to the histopathological changes, renal lesions were given scores from K0 (no lesions) to K5 (most severe). For scoring, the ratio of outer/lumen area at the cross section of tubules was measured using Axiovision Rel 4.8 software (Zeiss, Germany). In addition, 3 stages of histopathological alterations of kidney (Salamat et al., 2014) were used as a reference. Damage scores are as follows: K0, no lesions (the median of outer/lumen area was >10); K1, mild damage, such as infiltration of heterophils and cells in the proximal tubular lumens in a very limited area (the median of outer/lumen area was 8 to 9); K2, moderate damage, such as infiltration of heterophils and cells in proximal tubular lumens, and dilation of distal tubular lumens in a large area (the median of outer/lumen area was 5 to 7); K3, severe damage, such as infiltration of heterophils and cells in the proximal tubular lumens, dilation of tubular lumens, and proteinaceous casts (the median of outer/lumen area was approximately 4); K4, severe damage with unclear structure of renal tubules and glomeruli, and several proteinaceous casts (the median of outer/lumen area was approximately 3); or K5, severe damage with many necrotic cells, and proteinaceous casts (the median of outer/lumen area was 1 to 2, and most tubules were disintegrated). The damage levels of each chicken were as follows: K0 (control); K1 (B-4); K2 (B-2); K3 (C-2); K4 (A-1, C-4); K5 (B-1, C-1, C-3) . In the exposure group, chickens A-2, A-3, A-4, and B-3 did not show histopathological changes, and they were ranked K0.
The livers in chicken B-1 and all cisplatin-treated chickens showed mild hyperemia (Fig. S1 ). There were no lesions in the heart or lung in any of the chickens, and the control group did not show histopathological changes in any tissues.
Glycomics Analysis
For glycomics analysis, 10 chickens ( Cont.-1, -2, A-1,  B-1, B-2, B-4, C-1, -2, -3 , and -4) were selected according to the results of histopathological analysis and biochemical analysis, and plasma N-glycans were measured. A total of 40 plasma N-glycans were detected, and the levels of each glycan are shown by the ratio with glycan expression of plasma mix from the controls and pre-injection chickens (Table S2 ). The control group did not show any significant differences due to injection. Fourteen glycans were increased in the diclofenactreated kidney damaged chickens (Fig. 3, Table S3 ).
In the cisplatin group, glycan levels did not change significantly according to kidney injury, although the renal lesions were severe, and UA concentrations were high.
DISCUSSION
In the present study, we succeeded to cause various stages of nephrotoxicity in chickens after cisplatin (3.5 mg/kg) or 2 doses of diclofenac (1.5 to 2.0 mg/kg) treatments. The results of biochemical analyses indicated that UA, P, and LDH levels exceeded the respective normal ranges in several chickens. Both UA and P indicate severe renal lesions in chickens, but UA level was altered earlier than P level. According to the UA level, kidney function in the cisplatin group (C-1, -2, -3, and -4) would be markedly damaged 48 h after injection. In the diclofenac group, chicken A-1 had severe renal injury from 72 h after injection. The kidneys of chickens B-1 and B-2 were impaired with heavy renal failure after 24 h, and chicken B-1 died due to nephrotoxicity. Although LDH level increased in the treatment groups, it was difficult to identify the cause, because elevation of LDH is nonspecific, and is found in skeletal and cardiac muscle, liver, kidney, bone, and erythrocytes (Tully et al., 2009) .
Histopathological analysis of the kidney, liver, heart, and lung showed that chickens A-1, B-1, B-2, and B-4 and all cisplatin-treated chickens had damage almost specific to the kidney. Furthermore, the histology of the kidney might indicate that diclofenac caused AIN and cisplatin induced ATN in chicken, although the infiltration of leukocytes in interstitial in diclofenactreated chickens was not so severe compared to AIN in humans. In the case of diclofenac exposure, renal damage levels were completely different depending on the individual, and this tendency also was described in the reports mentioned above. There may be large differences in sensitivity even within a species. Therefore, the renal damage was shown by scores for comparison with other analyses.
Glycomics analysis showed that a high degree of kidney damage was associated with increased levels of both sialylated and non-fucosylated glycans in diclofenactreated chickens. Although not applicable to 6 glycans (No. 9, 22, 24, 26, 34, and 37) , this tendency was seen for the remaining 34 glycans. The synthesis pathway of N-linked glycans starts from the cytosolic surface of the endoplasmic reticulum membrane by addition of sugars, and in the early secretory pathway, the glycans have important roles in protein folding, oligomerization, quality control, sorting, and transport (Helenius and Aebi, 2001 ). The glycans acquire more complex structures and new functions in the Golgi complex (Helenius and Aebi, 2001 ). The trans compartment elaborates additional branching and capping reactions on complex N-glycans, and capping reactions are continued in the trans-Golgi network (Moremen et al., 2012) . Therefore, the final synthesis pathway, where sialic acids are attached, could be disturbed, or glycoproteins that have these glycans may be susceptible to the effects of kidney injury.
In cisplatin-treated chickens, there is no relation between glycan expression and kidney damage. Therefore, the glycans that increased in the diclofenac group may indicate the effects of diclofenac injection, rather than kidney injury itself. Another possibility is that glycans may have reflected parts of kidney injury, and not all types of renal damage.
With regard to AIN and ATN, although the mechanism underlying AIN is underestimated even in humans, it is generally accepted that the pathogenesis is based on an immunologic reaction against endogenous nephritogenic antigens or exogenous antigens processed by tubular cells, with cell-mediated immunity having a major pathogenic role (Praga and González, 2010) . In avian species, there is less information. However, it is reported that diclofenac causes nephrotoxicity due to reduction of UA transport by interfering with p-aminohippuric acid (PAH) channels in the chicken (Naidoo and Swan, 2009 ). The mechanism of diclofenac-induced renal failure in oriental whitebacked vultures has been proposed to be through inhibition of the modulating effect of prostaglandin on angiotensin II-mediated adrenergic stimulation (Jain et al., 2009) . Cisplatin induces DNA damage, either necrotic or apoptotic cell death, formation of reactive oxygen species, mitochondrial dysfunction, and caspase activation (Ramesh and Reeves, 2002) . These events cause both acute and chronic kidney injury, and the nephrotoxicity is characterized by activation of both proinflammatory cytokines and chemokines (Havasi and Borkan, 2016) .
The mechanisms of metabolism of diclofenac and cisplatin are different. Therefore, it is possible that glycans reflect the limited pathway of kidney injury, and glycan expression profiles change due to AIN but do not reflect ATN. Although further studies including investigation of species differences are needed, glycans have the potential to be useful biomarkers for AIN in avian species. The glycan expression profile may reflect some types of kidney injury, and these molecules have the potential for use as biomarkers for the evaluation of functional disorders in birds.
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